Learn how scientists use multi-omic approaches to identify functional changes that lead to cancer cell drug resistance and the development of new treatment strategies.

Learn about the technological innovations that can help you dramatically accelerate your immunotherapies and drug development.

Explore several case studies showing how IsoPlexis highly multiplexed bulk & single-cell capabilities enabled researchers to capture complexities connected to in vivo biology.

Learn about the technological innovations that can help you dramatically accelerate your immunotherapies and drug development

Explore the three key IsoPlexis capabilities that enable our researchers to capture complexities connected to in vivo biology with 'walk away' automation

Review data & case studies across three applications: Functional Immune Landscaping, Intracellular Signaling Omics & High-plex Automated Immunoassays

Explore the new IsoSpark: a personalized functional proteomics system for every lab

Review data & case studies across three applications: Functional Immune Landscaping, Intracellular Signaling Omics & High-plex Automated Immunoassays

Learn how our unique technology is playing a critical part in advancing cellular immunotherapy

Discover how IsoPlexis is changing the way cell therapies are developed & manufactured

Review several publications & case studies

Proteomic and genomic insights into COVID-19

Mapping functional immune responses at the single-cell and serum level to study COVID-19

Using single-cell proteomics to study how to create a balanced and durable immune response in COVID-19 patients and assist efforts to create future vaccines and therapies

Visualize how each immune cell is functionally communicating & contributing to orchestrating response

Learn how functional proteomics can help you gather predictive data to accelerate your research

Explore the intuitive and powerful visualizations, powered by the automated IsoSpeak software

How cell density and proliferation affect tumor cell metastasis and how they shape the development of novel therapies

How cytokine profiling and highly multiplexed proteomic analysis of three-dimensional models help identify proteins encouraging cell migration

How identifying a potential mechanism promoting tumor cell migration enables the development of a strategy to decrease tumor cell metastatic capacity

Learn how functional proteomics is filling the translational gap in single-cell technology

See how IsoPlexis' single-cell proteomic data is predicting resistance in tumor cells

Discover how single-cell phosphoproteomics informs targeted combination therapies

Understanding and detecting immune response and how function plays a role in developing the therapies that will make a difference in COVID-19

Therapeutic strategies to overcome pathogenesis of severe inflammation

How testing and diagnosis of the immune response to infectious disease will play a role

Using more predictive single cell proteomics in mouse models to understand correlative T cell potency in infectious disease vaccines

Understanding of more predictive T cell potency in mouse models important for understanding vaccine development

The challenges in pre-clinical vaccine development today that can be overcome by having potency tools and better ways to characterize human immune response

Discover how a trimeric extracellular moiety of APRIL has enhanced binding to BCMA and TACI compared with monomeric APRIL when incorporated into a CAR

Explore why trimeric APRIL-based CAR are efficient against BCMA-negative multiple myeloma

Learn why T cells transduced with a trimeric APRIL-based CAR are a promising approach for the treatment of multiple myeloma

Discover how using single-cell cytokine expression can be used to functionally profile CAR-Tregs

Explore approaches to profiling and characterization of engineered immune cells to mitigate unwanted effects

Identify the presence of small polyfunctional cell subpopulations that correlate with anti-tumor activities

Evaluate molecules that enhance the efficiency of cell therapy

Assess the effects of gene editing (CRISPR) on response in model systems

Explore IsoPlexis’ advanced immune-based approaches in systemic lupus erythematosus and adverse events like cytokine release syndrome and neurotoxicity in cell therapy

Determine correlates and drivers of adverse reactions using single-cell functional proteomics

Learn how these biomarkers may improve therapeutic development and intervention

Improve T-cell functionality for adoptive T cell therapy in metastatic colon cancer using small-molecule strategies

Use PSI to Unlock key insights into how the immune system can be modulated to improve development and solid tumor immunotherapeutic strategies

Discover novel correlative single-cell data from T-cells from the blood of colon cancer patients

Review advanced immune-based approaches in acute myeloid leukemia that combine chemotherapy with checkpoint therapy

Explore relevant biomarker strategies associated with these approaches

See how single-cell cytokine analysis system and PSI demonstrate that specific cytokine potency contributors correlate with overall survival

Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes

Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors

Uniquely correlate clinical anti-tumor responses with IsoPlexis data

Optimize combination cancer vaccines in melanoma using model systems

Discover the impact of therapy on MS by tracking inflammatory polyfunctionality in monocytes

Uncover NK contribution to Crohn's disease through proinflammatory polyfunctionality

Reveal the striking heterogeneity of polyfunctionality in PMF patient granulocytes suggesting directions for therapy in MPNA

Explore how cytokines reveal function in immunotherapy and the challenges in revealing mechanism & responders through blood cytokines & phenotype

Reveal highly polyfunctional immune cells that correlate to in-vivo response to immunotherapy

Uncover potent cytokine mechanism using Single-Cell PSI to reveal responders in trials with checkpoint inhibitors